Latest Insider Transactions at Akoya Biosciences, Inc. (AKYA)
This section provides a real-time view of insider transactions for Akoya Biosciences, Inc. (AKYA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Akoya Biosciences, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Akoya Biosciences, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 29
2024
|
Pascal Bamford Chief Clinical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+24.58%
|
-
|
|
Jun 11
2024
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-3.23%
|
$15,000
$2.08 P/Share
|
|
Jun 11
2024
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+3.13%
|
$0
$0.3 P/Share
|
|
Jun 06
2024
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-3.23%
|
$15,000
$2.01 P/Share
|
|
Jun 06
2024
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+3.13%
|
$0
$0.3 P/Share
|
|
Apr 01
2024
|
John Frederick Ek CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,272
-7.32%
|
$57,088
$4.56 P/Share
|
|
Mar 23
2024
|
Niro Ph.D Ramachandran Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,006
-0.96%
|
$8,024
$4.79 P/Share
|
|
Mar 23
2024
|
Frederic Pla Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,006
-1.94%
|
$8,024
$4.79 P/Share
|
|
Mar 23
2024
|
Brian Mc Kelligon President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,135
-3.08%
|
$28,540
$4.79 P/Share
|
|
Mar 20
2024
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-3.13%
|
$30,000
$4.97 P/Share
|
|
Mar 20
2024
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+3.04%
|
$0
$0.3 P/Share
|
|
Mar 13
2024
|
Robert G Shepler Director |
BUY
Bona fide gift
|
Indirect |
369,592
+50.0%
|
-
|
|
Mar 13
2024
|
Robert G Shepler Director |
SELL
Bona fide gift
|
Indirect |
369,592
-100.0%
|
-
|
|
Mar 13
2024
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-3.23%
|
$30,000
$4.94 P/Share
|
|
Mar 01
2024
|
Niro Ph.D Ramachandran Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,305
-1.09%
|
$13,830
$6.03 P/Share
|
|
Mar 01
2024
|
Frederic Pla Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,049
-1.94%
|
$12,294
$6.03 P/Share
|
|
Mar 01
2024
|
Jennifer Kamocsay General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,283
-3.2%
|
$19,698
$6.03 P/Share
|
|
Mar 01
2024
|
Brian Mc Kelligon President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,244
-2.68%
|
$61,464
$6.03 P/Share
|
|
Feb 22
2024
|
John Frederick Ek CFO |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+15.22%
|
-
|
|
Feb 22
2024
|
Niro Ph.D Ramachandran Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+14.16%
|
-
|
|
Feb 22
2024
|
Frederic Pla Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+24.9%
|
-
|
|
Feb 22
2024
|
Jennifer Kamocsay General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+25.45%
|
-
|
|
Feb 22
2024
|
Brian Mc Kelligon President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
87,500
+26.71%
|
-
|
|
Dec 19
2023
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-4.69%
|
$30,000
$4.48 P/Share
|
|
Dec 19
2023
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+4.48%
|
$0
$0.3 P/Share
|
|
Dec 12
2023
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-4.69%
|
$30,000
$4.25 P/Share
|
|
Dec 12
2023
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+4.48%
|
$0
$0.3 P/Share
|
|
Nov 20
2023
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
7,500
-4.69%
|
$30,000
$4.39 P/Share
|
|
Nov 20
2023
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+4.48%
|
$0
$0.3 P/Share
|
|
Nov 06
2023
|
Jennifer Kamocsay General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+30.77%
|
-
|
|
Nov 06
2023
|
Frederic Pla Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+29.83%
|
-
|
|
Sep 07
2023
|
Frederic Pla Chief Operating Officer |
BUY
Open market or private purchase
|
Indirect |
20,000
+37.96%
|
$80,000
$4.6 P/Share
|
|
Jun 12
2023
|
Thomas A. Raffin Director |
BUY
Open market or private purchase
|
Indirect |
2,020,000
+9.4%
|
$10,100,000
$5.0 P/Share
|
|
Jun 12
2023
|
Robert G Shepler Director |
BUY
Open market or private purchase
|
Indirect |
120,000
+24.51%
|
$600,000
$5.0 P/Share
|
|
Jun 12
2023
|
Matthew Winkler Director |
BUY
Open market or private purchase
|
Direct |
203,388
+17.12%
|
$1,016,940
$5.0 P/Share
|
|
Jun 12
2023
|
Scott Mendel Director |
BUY
Open market or private purchase
|
Direct |
20,000
+41.24%
|
$100,000
$5.0 P/Share
|
|
Jun 12
2023
|
Goldman Myla Lai Director |
BUY
Open market or private purchase
|
Direct |
20,000
+50.0%
|
$100,000
$5.0 P/Share
|
|
Jun 12
2023
|
John Frederick Ek CFO |
BUY
Open market or private purchase
|
Indirect |
20,000
+50.0%
|
$100,000
$5.0 P/Share
|
|
Jun 06
2023
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-3.17%
|
$25,000
$5.71 P/Share
|
|
Jun 06
2023
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+3.08%
|
$0
$0.3 P/Share
|
|
Mar 23
2023
|
Niro Ph.D Ramachandran Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,945
-1.09%
|
$13,615
$7.69 P/Share
|
|
Mar 23
2023
|
Brian Mc Kelligon President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
7,437
-4.65%
|
$52,059
$7.69 P/Share
|
|
Mar 23
2023
|
Frederic Pla Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,945
-4.58%
|
$13,615
$7.69 P/Share
|
|
Mar 20
2023
|
Jennifer Kamocsay General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+50.0%
|
-
|
|
Mar 20
2023
|
John Frederick Ek CFO |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+50.0%
|
-
|
|
Mar 14
2023
|
Brian Mc Kelligon President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.52%
|
$45,000
$9.53 P/Share
|
|
Mar 14
2023
|
Brian Mc Kelligon President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+2.94%
|
$0
$0.3 P/Share
|
|
Feb 23
2023
|
Niro Ph.D Ramachandran Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+11.16%
|
-
|
|
Feb 23
2023
|
Frederic Pla Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+32.0%
|
-
|
|
Feb 23
2023
|
Ehab El Gabry Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,250
+50.0%
|
-
|